These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 24940911)

  • 21. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity.
    Yano H; Andrews LP; Workman CJ; Vignali DAA
    Immunology; 2019 Jul; 157(3):232-247. PubMed ID: 31087644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments.
    Yoshimura T
    Cytokine; 2017 Oct; 98():71-78. PubMed ID: 28189389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial: The Role of Chemoattractants in the Tumor Microenvironment.
    Bernardini G; Zabel BA
    Front Immunol; 2019; 10():2671. PubMed ID: 31781129
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy.
    Mishra P; Banerjee D; Ben-Baruch A
    J Leukoc Biol; 2011 Jan; 89(1):31-9. PubMed ID: 20628066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemerin Suppresses Breast Cancer Growth by Recruiting Immune Effector Cells Into the Tumor Microenvironment.
    Pachynski RK; Wang P; Salazar N; Zheng Y; Nease L; Rosalez J; Leong WI; Virdi G; Rennier K; Shin WJ; Nguyen V; Butcher EC; Zabel BA
    Front Immunol; 2019; 10():983. PubMed ID: 31139180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving homing in T cell therapy.
    Vignali D; Kallikourdis M
    Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers.
    Arora S; Khan S; Zaki A; Tabassum G; Mohsin M; Bhutto HN; Ahmad T; Fatma T; Syed MA
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):720-736. PubMed ID: 35257861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukocyte trafficking: Can we bring the fight to the tumor?
    Pachynski R; Nazha J; Kohrt H
    Discov Med; 2016 Mar; 21(115):205-12. PubMed ID: 27115171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
    Weiss JM; Back TC; Scarzello AJ; Subleski JJ; Hall VL; Stauffer JK; Chen X; Micic D; Alderson K; Murphy WJ; Wiltrout RH
    Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19455-60. PubMed ID: 19892741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utilization of chemokines to combat cancer: the double-edged sword.
    Dell'Agnola C; Biragyn A
    Expert Rev Vaccines; 2007 Apr; 6(2):267-83. PubMed ID: 17408375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diverse role of chemokines in tumor progression: prospects for intervention (Review).
    Schneider GP; Salcedo R; Welniak LA; Howard OM; Murphy WJ
    Int J Mol Med; 2001 Sep; 8(3):235-44. PubMed ID: 11494048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CC chemokine receptor 5: the interface of host immunity and cancer.
    de Oliveira CE; Oda JM; Losi Guembarovski R; de Oliveira KB; Ariza CB; Neto JS; Banin Hirata BK; Watanabe MA
    Dis Markers; 2014; 2014():126954. PubMed ID: 24591756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pros and cons of chemokines in tumor immunology.
    Viola A; Sarukhan A; Bronte V; Molon B
    Trends Immunol; 2012 Oct; 33(10):496-504. PubMed ID: 22726608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of chemokines in tumor growth.
    Raman D; Baugher PJ; Thu YM; Richmond A
    Cancer Lett; 2007 Oct; 256(2):137-65. PubMed ID: 17629396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemokines and the microenvironment in neuroectodermal tumor-host interaction.
    Somasundaram R; Herlyn D
    Semin Cancer Biol; 2009 Apr; 19(2):92-6. PubMed ID: 19049876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
    Bronger H; Magdolen V; Goettig P; Dreyer T
    Cancer Metastasis Rev; 2019 Sep; 38(3):417-430. PubMed ID: 31482487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment.
    Chhabra G; Singh CK; Amiri D; Akula N; Ahmad N
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33802331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations.
    Guan M; Liu S; Yang YG; Song Y; Zhang Y; Sun T
    Int J Biol Macromol; 2024 May; 268(Pt 1):131679. PubMed ID: 38641274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target.
    Unver N
    Cytokine Growth Factor Rev; 2019 Dec; 50():13-18. PubMed ID: 31151747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key role of chemokines and chemokine receptors in inflammation, immunity, neoplasia, and infectious disease.
    Rottman JB
    Vet Pathol; 1999 Sep; 36(5):357-67. PubMed ID: 10490203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.